Orchestra BioMed Holdings (OBIO) Share-based Compensation (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Share-based Compensation of $11.0 million for Q1 2026, up 270.99% year-over-year from $3.0 million in Q1 2025, and up 2250.43% quarter-over-quarter from $468000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Share-based Compensation (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Share-based Compensation for 5 consecutive years, with $11.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 270.99% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (up 104.31% YoY), while the FY2025 annual figure was $6.6 million, down 10.81% from the prior year.
- Share-based Compensation improved to $11.0 million in Q1 2026 per OBIO's latest filing, from $468000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $11.0 million in Q1 2026 and bottomed at -$313000.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $2.6 million across 5 years, with a median of $919000.0 in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation slumped 134.06% — and 2025, when it jumped 5663.89%.
- Orchestra BioMed Holdings' Share-based Compensation stood at $863000.0 in 2022, then increased by 6.49% to $919000.0 in 2023, then plunged by 134.06% to -$313000.0 in 2024, then soared by 249.52% to $468000.0 in 2025, then jumped by 2250.43% to $11.0 million in 2026.
- Business Quant data shows OBIO's Share-based Compensation at $11.0 million in Q1 2026, $468000.0 in Q4 2025, and $359000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | 9.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.90 Mn |
| Mar 31, 2026 | 8.37 Mn |
| Dec 31, 2025 | 2.75 Mn |
| Sep 30, 2025 | 8.60 Mn |
| Jun 30, 2025 | 8.30 Mn |
| Mar 31, 2025 | 5.74 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 10.70 Mn |
| Jun 30, 2024 | 11.60 Mn |
| Mar 31, 2024 | 5.20 Mn |
| Dec 31, 2023 | 919,000.00 |
| Sep 30, 2023 | 5.20 Mn |
| Jun 30, 2023 | 6.60 Mn |
| Mar 31, 2023 | 5.20 Mn |
| Dec 31, 2022 | 863,000.00 |
| Sep 30, 2022 | 2.19 Mn |
| Jun 30, 2022 | 143,000.00 |
| Mar 31, 2022 | 70,000.00 |